About FDALive
FDALive.com Pricing Information
Videoconferencing: $1800
Audioconference: $400
Webcast:
> Single Viewer $250
> Group $1,000
Transcripts:
> 3 Business Day Services: $2000 - $2200
Group and Volume Discount Rates Available
Upcoming Meetings
Oncologic Drugs Advisory Committee
Meeting Date: 2/9/21-2/9/21
Meeting Details:
The committee will discuss supplemental biologics license application (sBLA) 125514/s-089, for KEYTRUDA (pembrolizumab), submitted by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The proposed indication (use) for this product is for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
Location: | Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. | Related News Links: | Not Available |
Time: | 10:00AM-2:00PM | ||
Materials: | |||
Recent Meetings
Past Meetings
Below is a listing of all committees. Select a committee to display all meetings available for that committee.
Live Meetings
There are no Live Broadcasts available at this time.